Novel Balugrastim Well Tolerated in Pilot Study in Patients with Breast Cancer

Share this content:
(ChemotherapyAdvisor) – Balugrastim, a novel once-per-cycle filgrastim with a fixed dose administration to prevent febrile neutropenia, is well tolerated in patients with breast cancer and warrants further study, according to results of a pilot study presented during the International Symposium on Supportive Care in Cancer, New York, NY, June 28-30, 2012.

Balugrastim was developed using an albumin-fusion platform technology by fusing r-metHuG-CSF to human serum albumin, reported David D. Shen, PhD, of Teva Biopharmaceuticals USA, Rockville, MD, USA, and colleagues.

They treated 13 patients with breast cancer with single, escalating, subcutaneous doses of balugrastim 50, 150, 300, and 450µg/kg 14 days prior to treatment with doxorubicin plus docetaxel. Serum levels of balugrastim were measured and relevant PK parameters, including AUC, Cmax, and half-life calculated. The PD parameter selected was mean change in absolute neutrophil count (ANC). The same PK and PD parameters were also determined in cycle 1 of chemotherapy.

The investigators observed a dose-dependent increase in bioavailability; ANC increased relative to historical data for pegfilgrastim, the comparator. At the balugrastim 450µg/kg dose level, PK parameters were comparable to 6mg fixed doses of subcutaneous pegfilgrastim, leading Dr. Shen to note that this “appears to be the optimal dose for further study.” Balugrastim was well tolerated in all patients treated.

The International Symposium on Supportive Care in Cancer is sponsored by the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs